Medivation Inc. will pay just $5 million up front, with the potential for another $85 million in development-based milestones and $245 million in sales milestones, for a stake in the PD-1 game through an exclusive global license to Curetech Ltd.'s late-stage molecule, pidilizumab (CT-011). Read More
Mapper of gene-control pathways directly in human disease tissue, Syros Pharmaceuticals Inc. plans to use $53 million in series B cash to advance cancer programs toward the clinic and widen the gene-control product engine into new therapeutic areas. Read More
DUBLIN – The recent reform of the notorious double-Irish tax avoidance scheme sends out a clear signal to those companies that currently avail of it, according to a senior tax policy official. Read More
Researchers have shown that flavanols – a compound found, among other foods, in cocoa beans – reversed age-related memory declines in healthy individuals in their 50s and 60s. Read More
Vitae Pharmaceuticals Inc. shares (NASDAQ:VTAE) picked up slightly Friday, gaining 46 cents, to close at $9.11, after soaring as high as $12.25, on positive top-line data from a phase I study in which an early stage experimental Alzheimer's disease (AD) therapy it co-developed with Boehringer Ingelheim GmbH reduced amyloid beta levels in cerebral spinal fluid (CSF) by more than 80 percent. Boehringer now will run additional phase I studies of the beta secretase (BACE) inhibitor, including a multiple-rising-dose trial expected to report data in the first half of 2015. Read More
SEOUL, South Korea – Vaccine makers in Asian emerging markets are stepping up their development efforts, while researchers are increasingly helping developing countries troubled by neglected diseases by partnering with domestic manufactures, often in neighboring countries. Read More
Five Prime Therapeutics Inc., of South San Francisco, disclosed an expansion of its respiratory disease research collaboration with Glaxosmithkline plc, of London, that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease. Read More
Rhythm Pharmaceuticals Inc., of Boston, said it presented results from a phase IIa trial assessing the safety and efficacy of relamorelin (RM-131) in 48 patients with chronic constipation at the American College of Gastroenterology scientific meeting in Philadelphia. Read More
Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported total revenues of $176.8 million for the third quarter, and non-GAAP net loss of $22.9 million, or 16 cents per share, besting consensus estimates, which has predicted a loss of 23 cents per share. Read More
Astrazeneca plc, of London, said the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the marketing authorization of Lynparza (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have complete or partial response to platinum-based chemotherapy. Read More
Two separate papers, one by researchers from the Memorial Sloan-Kettering Cancer Center and one by a team from the Massachusetts Institute of Technology (MIT), have used CRISPR genome editing technology to model complex genomic events in cancer. Read More
